Beckman Coulter's shares dropped around 7 percent after the firm disclosed that an ongoing issue surrounding its troponin test kits could lead to further restrictions on the test and may have a material impact on its results.
The Australian firm has taken aim at several firms in the research, molecular diagnostics, and agricultural genomics fields for allegedly infringing its patent covering methods of analyzing non-coding DNA sequences.
The Olympus Diagnostics business that Beckman Coulter acquired last summer provided a $120 million contribution for the fourth quarter. The firm beat analysts' consensus estimate, despite a drag from cash instrument sales during the quarter.
The automated benchtop system, called SPRIworks Fragment Library System I, is scheduled to be launched this quarter. It is capable of preparing up to 10 DNA libraries for the Illumina Genome Analyzer within five hours, according to Beckman.